Exact Sciences: A Strong Q4 Reveals Signs Of A Potential Inflection Point

Core Insights - The article discusses the performance of Exact Sciences (NASDAQ: EXAS) and highlights a 24% year-over-year growth in core revenue and a 31% increase in another unspecified metric in Q2 2023 [1] Company Performance - Exact Sciences reported a 24% year-over-year growth in core revenue [1] - The company experienced a 31% increase in another key performance indicator during the same period [1] Analyst Background - The author of the article is a full-time healthcare investor with a focus on innovative companies developing breakthrough therapies and pharmaceuticals [1]